Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    EXEED Posts 28.26% QoQ Growth from Early Q2, Expanding NEV Tech Experience Through Diverse Market Activities

    June 8, 2026

    Angel Yeast Showcases Yeast-Based Innovations for Animal Nutrition at TUYEM 2026

    June 8, 2026

    Dongfeng Liuzhou Motor’s 10th “67 Brand Customer Day” Advancing New Pathways for Global Growth

    June 7, 2026
    Facebook X (Twitter) Instagram
    • Home
    • Contact Us
    Sudan HeraldSudan Herald
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • More
      • Sports
      • Technology
      • Travel
    Sudan HeraldSudan Herald
    You are at:Home » CIL Announces Breakthrough in Benzene Recovery, Addressing Cost, Environmental, and Supply Challenges for OLED Display Manufacturers
    ACCESS Newswire

    CIL Announces Breakthrough in Benzene Recovery, Addressing Cost, Environmental, and Supply Challenges for OLED Display Manufacturers

    December 12, 2024
    Facebook Twitter Pinterest LinkedIn Tumblr Email

    TEWKSBURY, MA / ACCESSWIRE / December 12, 2024 / Cambridge Isotope Laboratories, Inc. (CIL) has successfully developed and implemented a game-changing benzene-d6 recovery program, addressing major pain points for manufacturers of organic light-emitting diode (OLED) displays. This innovative service reduces costs, minimizes environmental impact, and conserves scarce deuterium supplies.

    OLED display producers rely heavily on deuterated benzene (benzene-d6) as a critical starting material in their synthesis processes. However, this results in significant quantities of depleted benzene-d6, which is no longer usable but still retains considerable deuterium value. The disposal of such depleted material poses environmental challenges and substantial expenses.

    CIL’s benzene-recovery program offers a transformative solution. Customers can now return their depleted benzene-d6 to CIL, where it undergoes a proprietary re-enrichment process to restore it to virgin material quality. This service is available at a significant cost savings compared to new benzene-d6, providing significant economic benefits.

    Beyond the financial advantages, the program has far-reaching environmental and supply implications. It eliminates the need for costly disposal, reduces the demand on increasingly scarce deuterium (derived from heavy water, D2O) and conserves this vital resource for its growing applications in science, medical diagnostics, pharmaceuticals, and semiconductor production.

    Recycling offers several sustainable benefits. It reduces pollution by releasing fewer chemicals into the environment. Recycling also saves energy, as reprocessing chemicals like benzene requires less energy than producing them from raw materials. This leads to lower greenhouse gas emissions, helping to combat climate change.

    “This initiative underscores CIL’s commitment to collaboration and innovation in addressing our customers’ most pressing challenges,” said Cliff Caldwell, CEO of CIL. “By recovering and re-enriching depleted benzene-d6, we create a circular economy approach that is both economically and environmentally sustainable. As the world’s largest supplier of benzene-d6, we are uniquely positioned to deliver this groundbreaking service.”

    CIL’s benzene recovery program is the result of 12 months of dedicated development, expansion, and rigorous testing to ensure reliable capacity and uncompromising quality. CIL invites interested parties to inquire about the program’s details and how to participate.

    About Cambridge Isotope Laboratories, Inc.

    CIL is the world’s largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds used in research, environmental, pharmaceutical, medical diagnostic, OLED, and industrial markets. CIL subsidiary ABX, located in Dresden, Germany, is active in the development and commercialization of radio isotopic-labeled compounds for the diagnosis and treatment of cancers. CIL is an operating business owned by Otsuka Pharmaceutical. The CIL business consists of two facilities in the Boston, MA, area; a large isotope-enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany; and Eurisotop in Saclay, France. For more information on CIL, visit isotope.com.

    Contact Information

    Crissy Krisko
    crissyk@isotope.com
    1.978.269.1930

    SOURCE: Cambridge Isotope Laboratories, Inc.

    View the original press release on accesswire.com

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    The Heartbeat That Never Dies: How Neutrinovoltaic Technology Could End the Era of Battery-Dependent Medical Implants

    May 29, 2026

    Tyson Fury, The Gypsy King, Joins Datavault AI as International Spokesperson to Champion Athlete Data Monetization

    May 18, 2026

    Tabor Redefines Anti-Drone Testing with Software-Defined SDR Platform

    May 16, 2026
    Latest News

    Investor interest lifts UAE real estate in global index

    June 5, 2026

    Abu Dhabi advances climate adaptation tools

    June 5, 2026

    Dollar heads for weekly gain as yen nears 160 level

    June 5, 2026

    WHO says Congo Ebola response improves as challenges remain

    June 4, 2026

    Jangmi disrupts Tokyo flights and rail services

    June 3, 2026

    Uganda Ebola cases rise to 15 after six new infections

    June 3, 2026

    UAE and IAEA review nuclear safety after Barakah attack

    June 3, 2026

    Punjab wildfire chars 3,037 hectares in Kotli Sattian

    June 3, 2026
    © 2026 Sudan Herald | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.